Back to results
US 2022/0023402 A1Published application
Immunomodulatory pharmaceutical compositions including a synthetic peptide and transforming growth factor beta
AssigneeEnzo Biochem, Inc.
InventorsRobert Nussenblatt, Baoying Liu, Lai Wei, Elazar Rabbani, James J. Donegan
Life of this patent
Estimating the term…
Abstract
The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.
Claims5
A pharmaceutical composition, comprising
- a synthetic peptide which is IFKKISRDKSVTIYL (SEQ ID NO:
- 5) or VKGKKVYVTLTCAFR (SEQ ID NO:
- 6) or YGQEDVDVIGLTFRR (SEQ ID NO:
- 7) or LPLLANNRERRGIAL (SEQ ID NO:
- 8) or DTNLASSTIIKEGID (SEQ ID NO:
- 9) or VTVDVNSSEK (SEQ ID NO:
- 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO:
- 20) or GEPITVTVSVTN (SEQ ID NO:
- 22) or IPVTIDVTDN (SEQ ID NO:
- 25);
- and an enhancer selected from the group consisting of:
- transforming growth factor beta (TGF-β), rapamycin, fingolimod (FTY720), and a sphingosine kinase 1 inhibitor.
9 more elements
A pharmaceutical composition, comprising
- a synthetic peptide which is GEPIPVTVDVTNNTEKTVKK (SEQ ID NO:
- 2) or VTVDVTNNTEKTVKK (SEQ ID NO:
- 3) or IFKKISRDKSVTIYL (SEQ ID NO:
- 5) or VKGKKVYVTLTCAFR (SEQ ID NO:
- 6) or YGQEDVDVIGLTFRR (SEQ ID NO:
- 7) or LPLLANNRERRGIAL (SEQ ID NO:
- 8) or DTNLASSTIIKEGID (SEQ ID NO:
- 9) or VTVDVNSSEK (SEQ ID NO:
- 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO:
- 20) or GEPITVTVSVTN (SEQ ID NO:
- 22) or IPVTIDVTDN (SEQ ID NO:
- 25);
- and an enhancer selected from the group consisting of:
- high molecular weight hyaluronic acid, IL-2, IL-5, all-trans retinoic acid, anti-CD3, anti-CD28, vitamin D3, dexamethasone, IL-10, idolamine-2,3-dioxygenase, cholera toxin B subunit, ovalbumin, Flt2L, sirolimus, anti-thymocyte globulin, and CTLA-4/Ig.
11 more elements
A method of treating a patient suffering from an autoimmune disease, comprising
- administering to said patient a synthetic peptide which is GEPIPVTVDVTNNTEKTVKK (SEQ ID NO:
- 2) or VTVDVTNNTEKTVKK (SEQ ID NO:
- 3) or IFKKISRDKSVTIYL (SEQ ID NO:
- 5) or VKGKKVYVTLTCAFR (SEQ ID NO:
- 6) or YGQEDVDVIGLTFRR (SEQ ID NO:
- 7) or LPLLANNRERRGIAL (SEQ ID NO:
- 8) or DTNLASSTIIKEGID (SEQ ID NO:
- 9) or VTVDVNSSEK (SEQ ID NO:
- 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO:
- 20) or GEPITVTVSVTN (SEQ ID NO:
- 22) or IPVTIDVTDN (SEQ ID NO:
- 25).
9 more elements
A method of treating a patient suffering from an immune disease of the eye, comprising
- administering to said patient a synthetic peptide which is GEPIPVTVDVTNNTEKTVKK (SEQ ID NO:
- 2) or VTVDVTNNTEKTVKK (SEQ ID NO:
- 3) or IFKKISRDKSVTIYL (SEQ ID NO:
- 5) or VKGKKVYVTLTCAFR (SEQ ID NO:
- 6) or YGQEDVDVIGLTFRR (SEQ ID NO:
- 7) or LPLLANNRERRGIAL (SEQ ID NO:
- 8) or DTNLASSTIIKEGID (SEQ ID NO:
- 9) or VTVDVNSSEK (SEQ ID NO:
- 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO:
- 20) or GEPITVTVSVTN (SEQ ID NO:
- 22) or IPVTIDVTDN (SEQ ID NO:
- 25).
9 more elements
A method of treating a patient suffering from dysfunctional regulatory T-cells, comprising
- administering to said patient a synthetic peptide which is GEPIPVTVDVTNNTEKTVKK (SEQ ID NO:
- 2) or VTVDVTNNTEKTVKK (SEQ ID NO:
- 3) or IFKKISRDKSVTIYL (SEQ ID NO:
- 5) or VKGKKVYVTLTCAFR (SEQ ID NO:
- 6) or YGQEDVDVIGLTFRR (SEQ ID NO:
- 7) or LPLLANNRERRGIAL (SEQ ID NO:
- 8) or DTNLASSTIIKEGID (SEQ ID NO:
- 9) or VTVDVNSSEK (SEQ ID NO:
- 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO:
- 20) or GEPITVTVSVTN (SEQ ID NO:
- 22) or IPVTIDVTDN (SEQ ID NO:
- 25).
9 more elements
Dependencies are inferred from the claim text.